To expand our model systems for interrogation of ER signaling in high-grade serous cancer, we performed immunoblotting to assess ERα expression in a panel of established high-grade serous cell lines, with ERα-positive breast cancer cell lines serving as positive controls (Figure 3A). The gene discussed is ESR1; the disease is breast carcinoma.